copy and paste this google map to your website or blog!
Press copy button and paste into your blog or website.
(Please switch to 'HTML' mode when posting into your blog. Examples: WordPress Example, Blogger Example)
Input Form:Deal with this potential dealer,buyer,seller,supplier,manufacturer,exporter,importer
(Any information to deal,buy, sell, quote for products or service)
Home Page: European Journal of Cancer The European Journal of Cancer (EJC) integrates preclinical, digital, translational, and clinical research in cancer, from epidemiology, carcinogenesis and biology through to innovations in cancer treatment and patient care
List of Issues - European Journal of Cancer Explore the archive of issues from the European Journal of Cancer, featuring groundbreaking research and advancements in oncology
Table of Contents page: European Journal of Cancer EJC Biennial Report Genomic signatures as predictive biomarkers of homologous recombination deficiency in ovarian cancer Adriaan Vanderstichele, Pieter Busschaert, Siel Olbrecht, Diether Lambrechts, Ignace Vergote Published online: September 23, 2017 p5-14
Pan-cancer analysis of antibody-drug conjugate targets and putative . . . Antibody-drug conjugates (ADCs) are a rapidly expanding class of compounds in oncology Our goal was to assess the expression of ADC targets and potential downstream determining factors of activity across pan-cancer and normal tissues
Nivolumab plus relatlimab in advanced melanoma: RELATIVITY-047 4-year . . . In phase 2 3 randomized RELATIVITY-047, nivolumab plus relatlimab demonstrated a statistically significant improvement in progression-free survival (PFS), a clinically meaningful but not statistically significant improvement in overall survival (OS), and a numerically higher objective response rate (ORR) versus nivolumab alone in patients with previously untreated advanced melanoma
Pembrolizumab with or without chemotherapy in recurrent or metastatic . . . Pembrolizumab monotherapy and pembrolizumab-chemotherapy demonstrated superior overall survival (OS) versus cetuximab-chemotherapy (EXTREME) in the primary analysis of the phase III KEYNOTE-048 study of recurrent metastatic head and neck squamous cell carcinoma (R M HNSCC) in the first-line setting We report updated data with 5 years of follow-up
Application of blinatumomab, a bispecific anti-CD3 CD19 T-cell engager . . . Systemic sclerosis, a severe inflammatory autoimmune disease, shares a common thread with cancer through the underlying mechanism of inflammation This inflammatory milieu not only drives the immune dysregulation characteristic of autoimmune diseases but also plays a pivotal role in the pathogenesis of cancer Among the cellular components involved, B cells have emerged as key players in